Algert Global LLC Cuts Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Algert Global LLC trimmed its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 52.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 40,372 shares of the company’s stock after selling 45,056 shares during the period. Algert Global LLC owned about 0.07% of Health Catalyst worth $258,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares in the last quarter. Perfromance Wealth Partners LLC purchased a new position in Health Catalyst in the second quarter worth $64,000. Mackenzie Financial Corp purchased a new position in Health Catalyst in the second quarter worth $70,000. EntryPoint Capital LLC bought a new position in Health Catalyst in the 1st quarter valued at $98,000. Finally, Virtus Investment Advisers Inc. purchased a new stake in shares of Health Catalyst during the 1st quarter valued at $115,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $6.19, for a total value of $32,243.71. Following the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now directly owns 150,006 shares in the company, valued at $928,537.14. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,362 shares of company stock valued at $256,009 in the last three months. Company insiders own 2.70% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $7.91 on Thursday. The business’s fifty day moving average is $7.44 and its 200 day moving average is $6.88. The firm has a market cap of $466.97 million, a price-to-earnings ratio of -4.28 and a beta of 1.32. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $74.96 million. During the same period in the prior year, the business posted ($0.21) earnings per share. The company’s revenue was up 3.7% on a year-over-year basis. Equities analysts predict that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HCAT has been the topic of a number of research analyst reports. Stephens cut their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday. Piper Sandler dropped their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.58.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.